Search
CervoMed Inc
CRVOAdd to Watchlist
3.690USD
+0.590+19.03%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
34.16MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+19.03%
5 Days
+13.19%
1 Month
+23.00%
6 Months
-53.29%
Year to Date
-53.29%
1 Year
-37.77%
Key Figures
3.050Open
3.930High
1.63MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
17.58%Turnover Ratio
3.100Prev. Close
3.050Low
4.18MTurnover
LossP/E Static
3.22P/B
0.00%Div Yield TTM
-111.89%ROA
14.00052wk High
2.07Volume Ratio
-16.29MNet Profit
9.26MShares
-3.2803EPS TTM
-0.65Beta
-132.76%ROE
3.51052wk Low
28.38%Amplitude
100.00%Gross Margin
34.16MMarket Cap
0.62Reward/Risk
5.36%Risk Rate
TradingKey Stock Score of CervoMed Inc
Currency: USD Updated: 2026-06-30Key Insights
CervoMed Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 173 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.50.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CervoMed Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
CervoMed Inc Highlights
StrengthsRisks
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.01M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.01M.
Overvalued
The company’s latest PE is -0.94, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.35M shares, decreasing 68.39% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 202.18 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 10.77.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
19.500
Target Price
+529.03%
Upside Space
CervoMed Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
CervoMed Inc Info
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Ticker SymbolCRVO
CompanyCervoMed Inc
CEOAlam (John J)
Websitehttps://cervomed.com/
Related Instruments
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52283.700
+29.400 (+0.06%)
29935.500
+136.200 (+0.46%)
7493.000
+17.500 (+0.23%)
15216.000
-139.000 (-0.91%)
69509.000
+24.000 (+0.04%)
6291.400
+16.000 (+0.26%)
67.544
-0.424 (-0.62%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4053.440
+22.670 (+0.56%)
FAQs
What is the current price of CervoMed Inc (CRVO)?
The current price of CervoMed Inc (CRVO) is 3.69.
What is the symbol of CervoMed Inc?
The ticker symbol of CervoMed Inc is CRVO.
What is the 52-week high of CervoMed Inc?
The 52-week high of CervoMed Inc is 14.00.
What is the 52-week low of CervoMed Inc?
The 52-week low of CervoMed Inc is 3.51.
What is the market capitalization of CervoMed Inc?
The market capitalization of CervoMed Inc is 34.16M.
Is CervoMed Inc (CRVO) currently rated as Buy, Hold, or Sell?
According to analysts, CervoMed Inc (CRVO) has an overall rating of Buy, with a price target of 19.50.
What is the Earnings Per Share (EPS TTM) of CervoMed Inc (CRVO)?
The Earnings Per Share (EPS TTM) of CervoMed Inc (CRVO) is -2.98.